Induction Therapy Followed by Surgery for Unresectable Thymic Epithelial Tumours

Frontiers in Oncology

Bei Xu¹  Yue Fan²  Jihong Dong³  Shisuo Du⁴  Gang Chen⁵  Jianyong Ding⁶  Junzhen Liu⁷  Shuai Wang⁸  Jiahao Jiang⁸  Jian Gao⁸ 

[1] Western Medicine, Zhongshan Hospital, Fudan University, Shanghai, China;;Department of Integrated Traditional Chinese Medicine (TCM) &Department of Medical Oncology, Zhongshan Hospital, Fudan University, Shanghai, China;Department of Neurology, Zhongshan Hospital, Fudan University, Shanghai, China;Department of Pathology, Zhongshan Hospital, Fudan University, Shanghai, China;Department of Radiology, Zhongshan Hospital, Fudan University, Shanghai, China;Department of Radiotherapy, Zhongshan Hospital, Fudan University, Shanghai, China;Department of Thoracic Surgery, Zhongshan Hospital, Fudan University, Shanghai, China;

关键词: thymic epithelial tumors;    survival;    induction therapy;    complete resection;    stage;   

DOI  :  10.3389/fonc.2021.791647

来源: DOAJ

【 摘 要 】

Background and ObjectivesThe treatment of unresectable thymic epithelial tumours (TETs) remains controversial. Here, we present the efficacy and safety of induction therapy followed by surgery for unresectable TET.MethodsEighty-one patients with unresectable TETs treated with induction therapy followed by surgery were selected from a retrospective review of consecutive TETs from January 2005 to January 2021. Clinicopathological data were analyzed to assess tumour responses, resectability, adverse events, progression-free survival (PFS) and overall survival (OS).ResultsInduction therapy produced a major tumour response rate of 69.1%, a tumour response grade (TRG) 1-3 rate of 84.0% and an R0 resection rate of 74.1%. The most common toxic effects were all-grade neutropenia (35.8%) and anaemia (34.6%). The 10-year OS and PFS rates were 45.7% and 35.2%. Multivariate analysis showed that ypTNM stage, ypMasaoka stage, complete resection, and TRG were significant independent prognostic factors. Exploratory research revealed that different induction modalities and downstaging of T, N, M, TNM, or Masaoka classifications did not significantly alter the pooled hazard ratio for survival.ConclusionsInduction therapy followed by surgery is well tolerated in patients with unresectable TETs, with encouraging R0 resection rates. Multimodality management provides good control of tumors for unresectable TET patients.

【 授权许可】

Unknown